170 related articles for article (PubMed ID: 35162109)
1. Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
Buju RT; Akilimali PZ; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162109
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
Buju RT; Akilimali PZ; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457498
[TBL] [Abstract][Full Text] [Related]
3. Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo.
Buju RT; Akilimali PZ; Tran NT; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011850
[TBL] [Abstract][Full Text] [Related]
4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
5. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
Viruses; 2024 May; 16(5):. PubMed ID: 38793602
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir based therapy showed CD4
Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
[TBL] [Abstract][Full Text] [Related]
8. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
[TBL] [Abstract][Full Text] [Related]
9. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
[TBL] [Abstract][Full Text] [Related]
10. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
Lahiri CD; Brown NL; Ryan KJ; Acosta EP; Sheth AN; Mehta CC; Ingersoll J; Ofotokun I
AIDS; 2018 Sep; 32(15):2151-2159. PubMed ID: 30005011
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
12. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
13. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E
PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981
[TBL] [Abstract][Full Text] [Related]
14. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.
Mushy SE; Mtisi E; Mkawe S; Mboggo E; Ndega J; Yahya-Malima KI; Kamugunya D; Kilimba ES; Mlay BS; Muya A; Ngalesoni F
AIDS Res Ther; 2024 May; 21(1):35. PubMed ID: 38778318
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
16. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
Abudiore O; Amamilo I; Campbell J; Eigege W; Harwell J; Conroy J; Jiboye J; Lufadeju F; Amole C; Wiwa O; Anweh D; Agbaji OO; Akanmu AS
PLoS One; 2023; 18(5):e0284767. PubMed ID: 37196012
[TBL] [Abstract][Full Text] [Related]
17. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
[TBL] [Abstract][Full Text] [Related]
18. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
19. Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa.
Romo ML; Edwards JK; Semeere AS; Musick BS; Urassa M; Odhiambo F; Diero L; Kasozi C; Murenzi G; Lelo P; Wyka K; Kelvin EA; Sohn AH; Wools-Kaloustian KK; Nash D;
Clin Infect Dis; 2022 Sep; 75(4):630-637. PubMed ID: 34893813
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
